Array BioPharma Inc. (NASDAQ:ARRY) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01
| Entry into a Material Definitive Agreement. |
On May 4, 2017, Array entered into a clinical trial collaboration
and supply agreement with Merck Sharp Dohme B.V. (Merck) to
conduct a Phase 1b clinical trial to investigate the safety and
efficacy of the combination of binimetinib with Merck’s
anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in metastatic
colorectal cancer patients with microsatellite stable tumors.
Under the terms of the agreement, Merck will act as sponsor of
this clinical trial, and Array will supply Merck with binimetinib
for use in this clinical trial. This agreement provides that both
Array and Merck will jointly own clinical data generated from
this clinical trial. This agreement does not include a
non-competition provision that generally prohibits Merck or Array
from entering into agreements with third parties to perform other
clinical studies.
The Collaboration Agreement expires on delivery of the final
study report concerning the results of the clinical trial, unless
earlier terminated by either party in the event of the other
party’s uncured material breach or if there are certain safety
concerns, regulatory action prevents supply of one or both of
binimetinib or KEYTRUDA, or if either Party withdraws regulatory
approval for or discontinues development of its compound.
The foregoing description of the clinical trial collaboration and
supply agreement is a summary, is not complete and is qualified
in its entirety by reference to the full text of the actual
agreement, which will be filed as an exhibit to Array’s Annual
Report on Form 10-K for the fiscal year ending June 30, 2017.
A copy of Array’s related press release announcing the
transactions is attached hereto as Exhibit 99.1.
KEYTRUDA is a registered trademark of Merck Sharp Dohme Corp., a
subsidiary of Merck Co., Inc., Kenilworth, NJ, USA.
| Item 9.01 | Financial Statements and Exhibits. |
| ExhibitNo. | Description | |
| 99.1 |
Press release dated May 8, 2017 entitled Array BioPharma Announces Strategic Collaboration with Merck |
About Array BioPharma Inc. (NASDAQ:ARRY)
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382. Array BioPharma Inc. (NASDAQ:ARRY) Recent Trading Information
Array BioPharma Inc. (NASDAQ:ARRY) closed its last trading session down -0.17 at 7.18 with 3,052,582 shares trading hands.
